Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 9/20 | 0.40 |
| ▸ | PPARG | P37231 | 7/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | POLQ | O75417 | 1/20 | 0.37 |
| ▸ | ACP3 | P15309 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13949606 | 0.81 | POLQ (0.44) | EPHX2PPARGIDO1MAOAMAOB | |
| SCHEMBL916315 | 0.81 | TSHR (0.49) | POLBMAPK1IDO1KMT2A | |
| SCHEMBL916701 | 0.80 | KDM4E (0.36) | EPHX2PPARGMAOBACP3KDM4E | |
| SCHEMBL2008230 | 0.79 | EPHX2 (0.36) | EPHX2IDO1KDM4E | |
| SCHEMBL901668 | 0.79 | ALDH1A1 (0.44) | EPHX2IDO1MAOAMAOBKMT2A | |
| SCHEMBL642703 | 0.79 | FDPS (0.42) | ACP3KDM4EALDH1A1 | |
| SCHEMBL3086597 | 0.79 | IDO1 (0.34) | IDO1ACP3KDM4EKMT2AALDH1A1 | |
| SCHEMBL2958031 | 0.78 | ACP3 (0.38) | EPHX2PPARGPOLBMAPK1ACP3 | |
| SCHEMBL273117 | 0.77 | S1PR1 (0.40) | EPHX2PPARGMAPK1ALDH1A1 | |
| SCHEMBL9386757 | 0.77 | SRC (0.39) | KDM4EKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595315-B2 | Morpholine derivatives as norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| EP-1716126-B1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | LILLY CO ELI (US) | 2009-02-25 | — | — | EP | disclosed |
| US-20070060585-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY | 2007-03-15 | — | — | US | disclosed |
| EP-1716126-A1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005066144-A1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060585-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | SLC6A2, SLC18A2, SLC6A3 | EPHX2 2832/4885PPARG 3195/4885POLB 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.